Article Sidebar

pdf
Date Published: 09/04/2025
Abstract Views: 55
Views pdf: 42
DOI: https://doi.org/10.51298/vmj.v548i1.13293
Issue
Vol. 548 No. 1 (2025)
Section
Các bài báo
How to Cite
Đào Đức, T., & Trương Thị Ánh, H. (2025). RESULTS OF FIRST-LINE CETUXIMAB PLUS CHEMOTHERAPY IN TREATMENT FOR UNRESECTABLE RECURRENT OR METASTATIC COLORECTAL CANCER. Vietnam Medical Journal, 548(1). https://doi.org/10.51298/vmj.v548i1.13293

RESULTS OF FIRST-LINE CETUXIMAB PLUS CHEMOTHERAPY IN TREATMENT FOR UNRESECTABLE RECURRENT OR METASTATIC COLORECTAL CANCER

Tiến Đào Đức, Hồng Trương Thị Ánh

Main Article Content

Abstract

Background: Previous data from the phase III trials showed that adding cetuximab to chemotherapy in first-line recurrent or metastatic colorectal cancer treatment improved significantly the overall response rate (ORR) and progression-free survival (PFS) in patients with RAS wild-type tumors. Objective: Evaluate the ORR, PFS and toxicity of the cetuximab regimen combined with chemotherapy in first-line treatment of recurrent or metastatic colorectal cancer. Patients and method: Retrospective descriptive study from 28 patients with unresectable recurrent or metastatic colorectal cancer with RAS wild-type treated with cetuximab plus chemotherapy at Military Hospital 175, from January 2022 to December 2024. Results: ORR was 53,6%, median FPS was 5 months. The most common toxicity was acneiform exanthema (64,3%), of which grade 1-2 accounted for 50%. Other adverse events were mostly grade 1-2. Conclusion: First-line cetuximab plus chemotherapy has a favorable ORR with an acceptable toxicity, and is an optimal choice for patients with unresectable metastatic colorectal cancer with RAS wild-type. However, there is no significant PFS improvement.

Article Details

Keywords

Cetuximab, metastastic colorectal cancer, RAS wild-type, first-line treatment

References

1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021.
2. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23(36):9243-9.
3. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408-17.
4. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S-E, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2014;15(10):1065-75.
5. Qin S, Li J, Wang L, Xu J, Cheng Y, Bai Y, et al. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. J Clin Oncol. 2018;36(30):3031-9.
6. Colorectal metastatic CAPOX (XELOX) (capecitabine and oxaliplatin) 2024.
7. Colorectal metastatic FOLFOX6 (fluorouracil leucovorin oxaliplatin) 2024.
8. Colorectal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) and cetuximab (two weekly) 2024.
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.
10. Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). 2021;112(1):90-2.